Genzyme, a Sanofi Company Company Profile

01:03 EST 17th December 2018 | BioPortfolio

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at

News Articles [709 Associated News Articles listed on BioPortfolio]

Sanofi Genzyme’s foray into Indian MS market should be met with caution, says GlobalData

Sanofi Genzyme — specialty care global business unit of French pharma company Sanofi — has launched its multiple sclerosis (MS) drug in India, however, according to GlobalData, it should be cautio...

Sanofi Genzyme eyes major expansion in Cambridge

Sanofi Genzyme is reportedly looking to expand its footing into a bustling tech campus in the Cambridge, Mass. area.

Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 26062018] Prices from USD $350

Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investments report inclu...

Sanofi Genzyme Strategy, SWOT and Corporate Finance Report [Report Updated: 28082018] Prices from USD $175

Sanofi Genzyme Strategy, SWOT and Corporate Finance ReportSummarySanofi Genzyme Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report cov...

Sanofi-Genzyme BioVentures leads $10mm funding round for Evidation

Digital health company Evidation Health Inc. (behavior-driven outcome measurement products that use real life patient data from hundreds of applications and devices to assess a patient's best therapeu...

Sanofi bets big on India

The specialty care global business unit, Sanofi Genzyme, has recently launched its multiple sclerosis drug, in India

Sanofi schneidet besser als erwartet ab

Der Pharmakonzern Sanofi hat bei Umsatz und bereinigtem Gewinn dank guter Geschäfte der Biotechnologie-Sparte Genzyme und mit Entwicklungsländern im dritten Quartal ordentlich zugelegt. Die Erwart.....

Sanofi May Move Rare Disease to Boston Area

French drugmaker Sanofi is planning to deepen the rare diseases footprint of its Genzyme franchise at Cambridge, Massachusetts, US, where according to reports the business could move into new faciliti...

PubMed Articles [26 Associated PubMed Articles listed on BioPortfolio]

Characteristics of Occupational Injuries in a Pharmaceutical Company in Iran.

To prioritize occupational hazards in a Pharmaceutical Company in Iran using the analytical hierarchy process (AHP).

A Man (or a Woman) is Known by the Company He/She Keeps.

Notes from the Field: Lead Exposures Among Employees at a Bullet Manufacturing Company - Missouri, 2017.

Significant Decreasing Trend in Low Back Injuries in a Beverage Company.

Work-related injuries in the U.S. have steadily declined over the past three decades.

Dupixent, a New Entrant In the Asthma Lists.

Sanofi and Regeneron's Dupixent (dupilumab)-which is already approved for atopic dermatitis-has an FDA action date of October 20 for its asthma indication. It will join Nucala, (mepolizumab), Cinqair ...

Clinical Trials [168 Associated Clinical Trials listed on BioPortfolio]

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Primary objectives: - To describe the immune response to each dengue serotype before and after each vaccination with sanofi pasteur's CYD dengue vaccine. - To evaluate t...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

The purpose of this study is to determine the safety and efficacy of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor) Conditioning Regimen in Patients with...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)

The purpose of this research study is to compare subject comfort during and after injection with NADGL and Captique® Injectable Gel, in the nasolabial folds. Captique® is an FDA-approve...

Companies [1520 Associated Companies listed on BioPortfolio]

Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals t...

Sanofi and Warp Drive Bio

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human va...


SANOFI concentrate their research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide: D...

Sanofi Genzyme

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, prov...

sanofi-aventis U.S.

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. San...

More Information about "Genzyme, a Sanofi Company" on BioPortfolio

We have published hundreds of Genzyme, a Sanofi Company news stories on BioPortfolio along with dozens of Genzyme, a Sanofi Company Clinical Trials and PubMed Articles about Genzyme, a Sanofi Company for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genzyme, a Sanofi Company Companies in our database. You can also find out about relevant Genzyme, a Sanofi Company Drugs and Medications on this site too.

Quick Search


Relevant Topics

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Corporate Database Quicklinks

Searches Linking to this Company Record